YOUR BIOLOGICAL RESEARCH PARTNER

Explore Metabolomics with Metabolon

For more than 25 years, Metabolon has set the standard for reliable, accurate, and reproducible metabolomics data and analysis.

Leaders in Metabolomics

Metabolon sets the gold standard in metabolomics research by combining comprehensive study design and sample collection services with advanced instrumentation and proprietary data generation methods to deliver high-quality data and unbeatable services.

Our proprietary biochemical reference library of more than 5,400 level 1 and level 2 annotated metabolites ensures your project yields truly actionable data, and our report generation services and bioinformatics tools deliver your data to you in ways that make it quick and easy to further your investigation and uncover novel insights.

Supported by a team of expert metabolomics scientists and bioinformaticians, our approach delivers accurate, reproducible data with the broadest coverage of the metabolome to accelerate discoveries and achieve faster study objectives for academic, clinical, and commercial projects.

0+

Global Sample Capacity

0+

Projects

0+

Sample Types

0+

Disease Studies

0+

Metabolites

Certified

CAP | CLIA | ISO

Featured Applications of Metabolomics

As a recognized pioneer and leader in metabolomics, Metabolon is the industry’s most experienced and trusted partner. With a 25-year legacy of innovation, we continue to push the field forward in exciting new ways. These web pages are not intended to cover the full breadth of metabolomics applications. Instead, they spotlight select hot topics—areas whose impact may surprise both long-time experts and those new to the field.

Applied Markets

Metabolomics is ideally suited to substantiate product claims by providing scientific data that is adjacent and relevant to the phenotype

Drug Discovery

You are missing vital mechanistic, safety and efficacy information that can drive decisions and save money and time.

Exposome

Without Metabolomics, critical connections between exposure, mechanism, and outcome remain unseen.

mayo clinic
mayo clinic
mayo clinic
mayo clinic
mayo clinic
mayo clinic

Why Metabolon Leads the Field in Untargeted Metabolomics

Our Global Discovery Panel utilizes advanced liquid chromatography-mass spectrometry (LC-MS) technology to provide high-fidelity, reproducible analyses of biological systems, enabling the identification of novel biomarkers and revealing changes in key biological pathways. Our rigorous quality control measures ensure data integrity, and our advanced bioinformatics help you pull meaningful insights from complex datasets to further your research.

1,800,000+

Samples Analyzed

25

Years Experience

4,000+

Publications

45

Employees with PhDs

5,400+

Metabolites

15,000+

Completed Projects

Core Technical Benefits

Metabolon’s value goes beyond the data we generate. Browse some of our core technical competencies.

Broad Coverage of the Metabolome

Metabolon’s platform provides the most extensive coverage of metabolites commercially available, delivering a comprehensive view of the metabolome. This depth of data allows for a better understanding of biological systems, informed by a fuller array of metabolic interactions.

Accurate Quantification and High Reproducibility

Our proprietary methodology ensures high standards for quantification and reproducibility of data across multiple batches and projects, reducing variability and increasing confidence in metabolomics insights that may not be possible with other metabolomics service providers. This accuracy supports stronger, statistically significant findings across all stages of research.

Unmatched Expertise in Metabolite Identification

Metabolon’s extensive, curated library allows for high-confidence identification of metabolites, including rare or challenging compounds. Our expertise in metabolite identification is critical for producing actionable and high-impact biological data.

Validation and Quality Standards

Our validated workflows meet ISO 9001:2015 quality management standards. We are CAP and CLIA certified, and applicable targeted metabolomics services meet Good Clinical Practices. Our commitment to quality improves the confidence and impact of your data and strengthens regulatory submissions.

Expert Interpretation and Bioinformatics Support

With an interdisciplinary team of metabolomics specialists, bioinformaticians, and biochemists, Metabolon provides expert data interpretation and insights. Our collaborative support helps you derive meaningful conclusions and enhances the overall value of your research.

Truly Actionable Data

Our data is cited in more than 350 publications in the last 3 years – that’s 10x more than the next best metabolomics provider.* Where other service providers discuss the volume of their data, we emphasise coverage and quality, resulting in truly actionable insights.
Source: Pubmed.

icon quotes

“Metabolon has developed a solid, scalable solution to the non-trivial problem of metabolomics biochemical interpretation, specifically tailored to their world-leading data acquisition platform. Leveraging decades of experience in data curation, Metabolon provides intuitive visualization tools for pathway analysis and disease association, adding even more value to an already outstanding product.”

David Broadhurst, PhD
Professor of BioSystems Data Science at Edith Cowan University, Australia.

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.